Science advances · 2026
A subunit vaccine for multiple respiratory viruses.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Qinzhe, Huang Wei-Chiao, Mahmoud Sara H, Ye Chengjin, Sia Zachary R, Song Yiting, Jiao Yang, Luo Yuan, Zhou Shiqi, Pul Reuben M, Kutscher Hilliard L, Hsu Wen-Ling, Arpin Dominic, Ortega Joaquin, Martinez-Sobrido Luis, Davidson Bruce A, Lovell Jonathan F
Аннотация
Seasonal influenza viruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and respiratory syncytial virus (RSV) drive substantial mortality worldwide. Vaccines against these respiratory viruses are traditionally administered separately, and, while some emerging technologies have shown promise to address multiple pathogens simultaneously, subunit protein vaccines have lagged behind. Here, we describe a nanoliposome-based vaccine platform that codisplays recombinant hemagglutinin ectodomains from three seasonal influenza strains, the SARS-CoV-2 receptor binding domain, and the RSV F ectodomain, in prefusion form. In mouse, ferret, and cotton rat models, immunization elicited protective immunity against the three major respiratory viruses, with antibody responses comparable to those induced by the corresponding monovalent formulations. These findings highlight the potential for multivalent recombinant protein vaccines delivered via nanoliposome carriers to provide immunologic protection against a broad spectrum of respiratory viruses.